Third, previous ideal IBD anti-TNFα predictors like TREM1 are also questioned as not a robust predictor of clinical or endoscopic outcomes following adalimumab treatment in patients with UC or CD (Verstockt et al., 2022). This evidence concerns the gene TNF and irritable bowel syndrome.